These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 20012301)

  • 1. Functional analysis of LOXL2 in pancreatic carcinoma.
    Rückert F; Joensson P; Saeger HD; Grützmann R; Pilarsky C
    Int J Colorectal Dis; 2010 Mar; 25(3):303-11. PubMed ID: 20012301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma.
    Kim IK; Lee YS; Kim HS; Dong SM; Park JS; Yoon DS
    Sci Rep; 2019 Apr; 9(1):5933. PubMed ID: 30976063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of LOXL2 in the promotion of pancreas cancer metastasis.
    Park JS; Lee JH; Lee YS; Kim JK; Dong SM; Yoon DS
    Oncotarget; 2016 Jul; 7(27):42539-42552. PubMed ID: 27285767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer.
    Tanaka N; Yamada S; Sonohara F; Suenaga M; Hayashi M; Takami H; Niwa Y; Hattori N; Iwata N; Kanda M; Tanaka C; Kobayashi D; Nakayama G; Koike M; Fujiwara M; Fujii T; Kodera Y
    Sci Rep; 2018 Jun; 8(1):9846. PubMed ID: 29959362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
    Arumugam T; Ramachandran V; Fournier KF; Wang H; Marquis L; Abbruzzese JL; Gallick GE; Logsdon CD; McConkey DJ; Choi W
    Cancer Res; 2009 Jul; 69(14):5820-8. PubMed ID: 19584296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC.
    Lee YS; Kim HS; Kim HJ; Kang HW; Lee DE; Kim MJ; Hong WC; Kim JH; Kim M; Cheong JH; Park JS
    J Mol Med (Berl); 2023 Nov; 101(11):1449-1464. PubMed ID: 37737908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
    PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas.
    Peinado H; Moreno-Bueno G; Hardisson D; Pérez-Gómez E; Santos V; Mendiola M; de Diego JI; Nistal M; Quintanilla M; Portillo F; Cano A
    Cancer Res; 2008 Jun; 68(12):4541-50. PubMed ID: 18559498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.
    Le Calvé B; Griveau A; Vindrieux D; Maréchal R; Wiel C; Svrcek M; Gout J; Azzi L; Payen L; Cros J; de la Fouchardière C; Dubus P; Guitton J; Bartholin L; Bachet JB; Bernard D
    Oncotarget; 2016 May; 7(22):32100-12. PubMed ID: 27050073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway.
    Hong X; Yu JJ
    Int J Oncol; 2019 May; 54(5):1676-1690. PubMed ID: 30816490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of ATF-2 enhances epithelial-mesenchymal transition and gemcitabine sensitivity in human pancreatic cancer cells.
    Wu X; Liu Z; Guo K; Ma G; Song S
    J Cell Biochem; 2019 Mar; 120(3):4463-4471. PubMed ID: 30367508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neural Wiskott-Aldrich syndrome protein (N-WASP) promotes distant metastasis in pancreatic ductal adenocarcinoma via activation of LOXL2.
    Kim HS; Lee YS; Dong SM; Kim HJ; Lee DE; Kang HW; Kim MJ; Park JS
    Oncol Res; 2024; 32(4):615-624. PubMed ID: 38560567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.
    Chen S; Wang Y; Zhang WL; Dong MS; Zhang JH
    Mol Med Rep; 2017 Apr; 15(4):1461-1470. PubMed ID: 28259943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
    Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
    J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
    Hagmann W; Jesnowski R; Löhr JM
    Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
    Li Y; VandenBoom TG; Kong D; Wang Z; Ali S; Philip PA; Sarkar FH
    Cancer Res; 2009 Aug; 69(16):6704-12. PubMed ID: 19654291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
    Gao CC; Xu XL; Li F; Gong BG; Liu S; Cui YQ; Sun HC; Xu PY; Zheng YM; Jiang H
    Tumour Biol; 2016 Jun; 37(6):7555-64. PubMed ID: 26684804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase.
    Funamizu N; Kamata Y; Misawa T; Uwagawa T; Lacy CR; Yanaga K; Manome Y
    Pancreas; 2012 Jan; 41(1):107-13. PubMed ID: 21926937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.